Tokyo, Japan – Plexus Ventures is pleased to announce the successful conclusion of an out-licensing project of its client Fujifilm Kyowa Kirin Biologics Co., Ltd. Plexus Ventures provided professional services to Fujifilm Kyowa Kirin Biologics to partner the European rights for FKB327, a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics, with Mylan N.V.
“The opportunity to represent Fujifilm Kyowa Kirin Biologics in the partnering of their lead compound, whose Marketing Authorization Application is currently under review by the European Medicines Agency, is a great honor,” said Richard Brown, General Partner and Head, Tokyo Office of Plexus Ventures. “The high-quality development and manufacturing of FKB327 and the excellent reputation of Fujifilm Kyowa Kirin Biologics and its parent companies, FUJIFILM Corporation and Kyowa Hakko Kirin Co., Ltd., distinguishes FKB327 from other adalimumab biosimilars under development.”
President and CEO of Fujifilm Kyowa Kirin Biologics, Dr. Yoshifumi Torii, remarked, “We are very pleased with the strong and knowledgeable support of Plexus Ventures in all phases of the process leading to this important agreement with Mylan. Plexus Ventures’ broad industry network allowed us to select the optimal partner for commercializing FKB327 in Europe.”
Details regarding the transaction are provided in the press release of Fujifilm Kyowa Kirin Biologics: [http://fujifilmkyowakirin-biologics.com/en/information/pack/pdf/article_180411en.pdf]
